BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Sacubitril/valsartan Total	Control Events	Control Total	Weight	Risk Ratio M-H, Fixed, 95% CI
2.3.1 English						
AWAKE-HF 2019	5	69	4	70	0.2%	1.27 [0.36, 4.52]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	1	231	1	232	0.0%	1.00 [0.06, 15.96]
OUTSTEP-HF	19	309	28	310	1.2%	0.68 [0.39, 1.19]
PARADIGM-HF 2014	1937	4203	2142	4229	94.6%	0.91 [0.87, 0.95]
PIONEER-HF 2018	41	440	74	441	3.3%	0.56 [0.39, 0.79]
PRIME-HF 2019	7	60	9	58	0.4%	0.75 [0.30, 1.89]
Subtotal (95% CI)		**5320**		**5348**	**99.8%**	**0.90 [0.86, 0.94]**
Total events	2010		2258			
Heterogeneity: Chi² = 8.70, df = 5 (P = 0.12); I² = 43%						
Test for overall effect: Z = 4.93 (P < 0.00001)						
2.3.2 Chinese						
Li J 2019 (1)	3	62	5	64	0.2%	0.62 [0.15, 2.48]
Subtotal (95% CI)		**62**		**64**	**0.2%**	**0.62 [0.15, 2.48]**
Total events	3		5			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.68 (P = 0.50)						
Total (95% CI)		**5382**		**5412**	**100.0%**	**0.89 [0.86, 0.94]**
Total events	2013		2263			
Heterogeneity: Chi² = 8.99, df = 6 (P = 0.17); I² = 33%						
Test for overall effect: Z = 4.96 (P < 0.00001)						
Test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.60), I² = 0%